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Abstract
Background: Atrial fibrillation (AF) often co-exists with renal function (RF) impair-
ment. We investigated the characteristics and management of AF patients across 
creatinine clearance strata and potential changes in the use of nonvitamin K oral anti-
coagulants (NOAC) according to different equations for estimation of RF.
Methods: In this post hoc analysis of the BALKAN-AF survey, patients were clas-
sified according to RF (Cockcroft-Gault formula) as: preserved/mildly depressed RF 
(P-RF) ≥50 mL/min, moderately depressed RF (MD-RF) 30-49 mL/min, and severely 
depressed RF (SD-RF) <30 mL/min.
Results: Of 2712 enrolled patients, 2062 (76.0%) had data on RF. Patients with SD-RF 
and MD-RF were older, had higher mean value of European Heart Rhythm Association 
score, stroke and bleeding risk scores, and more comorbidities than patients with P-RF 
(all P < .05). They received oral anticoagulants (OAC), AF catheter ablation, and electrical 
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1  | INTRODUC TION
Atrial fibrillation (AF) is often accompanied by renal function (RF) im-
pairment of various degree1, coexisting with chronic kidney disease 
(CKD) in about 15%-20% of patients2, especially among the elderly 
and those with concomitant risk factors such as, for example, diabe-
tes mellitus (DM), hypertension or obesity.3
Kidney damage (ie, albuminuria) or impaired kidney function (ie, 
glomerular filtration rate [GFR] <60 mL/min/1.73 m2) for 3 months 
or more is defined as CKD.4 Estimated GFR (eGFR) may be cal-
culated from the serum creatinine using various equations1,5, and 
the Kidney Disease: Improving Global Outcomes (KIDIGO) group 
endorsed Chronic Kidney Disease Epidemiology Collaboration 
group (CKD-EPI) equation.5 The CKD-EPI equation is less biased 
and more precise in GFR estimation than Cockcroft-Gault (CG) or 
MDRD (Modification of Diet in Renal Disease).1 In case of manage-
ment with nonvitamin K oral anticoagulants (NOACs), RF should 
be assessed by calculating creatinine clearance (CrCl) using the CG 
method as in most NOAC trials.6 Patients are eligible for NOACs if 
CrCl is ≥30 mL/min in case of dabigatran or CrCl is ≥15 mL/min in 
case of rivaroxaban, apixaban, and edoxaban. Importantly, NOAC 
dose should be selected as per the drug label.6,7
There is a bidirectional interaction between AF and CKD. AF 
facilitates the development or progression of CKD, whereas de-
creased RF is associated with increased prevalence and incidence 
of AF. AF and CKD share common abnormal molecular signaling 
pathways contributing to their pathogenesis. There is a well-es-
tablished interrelationship between heart and the kidney, thus 
dysfunction of one organ negatively affects the other.8-10 Both 
nonend-stage CKD and the disease requiring renal-replacement 
therapy are independently associated with higher risk of stroke, 
bleeding, myocardial infarction, and mortality in patients with 
AF.11,12 Assessment of RF is crucial for adequate NOACs dose se-
lection in patients with AF.6
Reportedly, the adherence to AF guidelines in the Balkan region 
is low13,14, and data on the management of patients with AF across 
the RF strata are lacking. Given the differences in socioeconomic 
and healthcare system-related features between the Balkan region 
and Western Europe, describing patterns of AF management in 
clinical practice in the Balkans may identify region-specific knowl-
edge gaps and inform strategies for optimizing the management of 
patients with AF in the participating Balkan countries.15
The aims of this study were to: (a) investigate the baseline char-
acteristics of patients with AF across CrCl strata, (b) determine “re-
al-world” management of AF patients according to their RF, and (c) 
assess potential changes in decision making on the use of NOACs 
according to different equations for estimation of RF.
2  | METHODS
The design of the BALKAN-AF survey has been previously pub-
lished.15 A 14-week prospective, international, multicenter “snap-
shot” registry of consecutive patients with electrocardiographically 
documented nonvalvular AF was created by the Serbian Atrial 
Fibrillation Association (SAFA). The registry was announced to the 
National Cardiology Societies and Associations or Working Groups 
in the Balkan countries. The survey was conducted from December 
2014 to February 2015 in seven Balkan countries (Albania, Bulgaria, 
Bosnia & Herzegovina, Croatia, Montenegro, Romania, and Serbia). 
Individuals were enrolled into the study, irrespective whether AF 
was the main reason for outpatient visit or inpatient stay in the 
hospital. Admissions for cardioversion or AF catheter ablation were 
also included. Patients were treated by a cardiologist or an inter-
nal medicine specialist if cardiologist was not available. Patients 
were recruited by academic and nonuniversity hospitals and out-
patient health centers (a total of 49 centers) in Albania, Bosnia & 
Herzegovina, Bulgaria, Croatia, Montenegro, Romania, and Serbia. 
cardioversion less often than those with P-RF (all P < .05). Rate control, no OAC, single-
antiplatelet therapy (SAPT) alone, and loop diuretics were more prevalent in patients 
with SD-RF and MD-RF than in subjects with P-RF (all P < .005). An important change 
in NOAC therapy could appear in <1% of patients (Modification of Diet in Renal Disease 
formula) and in <1% of patients (Chronic Kidney Disease Epidemiology Collaboration 
group formula).
Conclusions: Patients with SD-RF and MD-RF were older, more symptomatic, had 
higher stroke and bleeding risk and more comorbidities than those with P-RF. They 
were less likely to receive OAC and more likely to use rate control strategy, SAPT 
alone, and no OAC than subjects with P-RF.
K E Y W O R D S
atrial fibrillation, BALKAN-AF survey, creatinine clearance, oral anticoagulant therapy, renal 
function
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Each country recruited university and nonuniversity hospitals and 
outpatient health centers situated in different cities or rural areas. 
The centers were selected by the respective National Coordinator. 
Those centers had to accurately reflect AF management in particular 
country in daily clinical practice. A signed patient informed consent 
form was obtained before enrolment. The study protocol is consist-
ent with the ethical guidelines of the 1975 Declaration of Helsinki.
The exclusion criteria were age <18 years, prosthetic mechan-
ical heart valves or significant valvular disease with indication for 
surgical repair.
Data were documented using an electronic case report form (eCRF) 
designed by SAFA. The eCRF included: patient characteristics, patient 
presentation and healthcare setting, diagnostic procedures for AF 
within the last 12 months and at enrolment, and AF management at 
enrolment and at discharge. All the cardiovascular risk factors, diseases, 
and risk scores were defined based on individual European Society of 
Cardiology guidelines, other current guidelines, scientific statements, 
and textbooks presented previously in supplementary information.13
Following equations were used for RF assessment: (a) the CG for-
mula for CrCl16, (b) MDRD17, and (c) CKD-EPI.5 Using the CG formula 
for CrCl patients were categorized to three groups as follows: (a) pre-
served/ mildly depressed RF (P-RF) ≥50 mL/min, (b) moderately de-
pressed RF (MD-RF) 30-49 mL/min, and (c) severely depressed RF 
(SD-RF) <30 mL/min. Baseline characteristics and management of pa-
tients stratified into three groups according to CG formula for CrCl were 
performed. The cut-off values were selected according to those used in 
the landmark NOAC trials.6 The same cut-offs were chosen for other 
equations reported in this study. We reported the proportion of pa-
tients re-allocated to each class of RF for each specific formula used for 
RF evaluation. Some differences are present in the number of individ-
uals allocated to each category of RF according to different equations.
Symptoms of AF were classified according to European Heart 
Rhythm Association (EHRA) symptom score (ie, 1—AF does not 
cause any symptoms, 2—typical daily activity not affected by symp-
toms related to AF, 3—typical daily activity affected by AF symp-
toms, 4—normal daily activity discontinued).18
Stroke risk was estimated using the CHA2DS2-VASc (congestive 
heart failure, hypertension, age ≥ 75 years, diabetes, stroke/tran-
sient ischemic attack (TIA), vascular disease, age 65-74 years, sex 
category) score.19 Bleeding risk was evaluated according to the HAS-
BLED (hypertension, abnormal renal/liver function, stroke, bleeding 
history or predisposition, labile International Normalised Ratio (INR), 
elderly (>65 years), drugs or alcohol concomitantly) score.19,20
Because of relatively short period of the survey systematic monitoring 
of centers and follow-up visits was not performed. National coordinators 
and investigators were responsible for verification of the consecutiveness 
of enrolled patients and data correctness and completeness.
2.1 | Statistical analysis
Univariate analysis was used for both continuous and categori-
cal variables. Categorical variables were reported as absolute 
frequencies and percentages, and continuous variables as mean 
value and standard deviation (SD). Comparison of categorical vari-
ables among RF categories was calculated using chi-square test. 
Normal distribution was checked using the Shapiro-Wilk test and 
a Q-Q plot. Homogeneity of variances was checked using Leven's 
test. Analysis of variance was performed using one-way ANOVA 
with post hoc Tukey test. The descriptive analysis included baseline 
characteristics of patients according to their RF using CG formula 
and characteristics of AF patients with HF stratified by their RF. The 
association of patient-, AF-, healthcare system- and management-
related variables with the eGFR strata was evaluated using uni-
variate linear regression. The variables with statistically significant 
association on univariate linear regression analysis were entered into 
multivariable linear regression model. Results are expressed as odds 
ratio with 95% confidence interval. A two-sided P value of <.05 was 
interpreted as statistically significant. All analyses were performed 
using SAS software version 9.4 (SAS Institute, Inc, Cary, NC, USA).
3  | RESULTS
Of 2712 patients enrolled in seven Balkan countries, complete data 
on RF based on CG formula for CrCl were available for 2062 (76.0%). 
Of the study cohort, 1677 patients (81.3%) had P-RF, 308 (14.9%) 
had MD-RF, and 77 (3.8%) had SD-RF, Table 1.
3.1 | Demographic and AF-related characteristics
Patients with SD-RF and MD-RF were older, with higher mean EHRA 
symptom score, less likely to be smokers, but more likely to have 
permanent AF than those with P-RF (all P < .05), Table 1.
3.2 | Physical findings and comorbidity
Patients with SD-RF and MD-RF were more likely to have various co-
morbidities, such as prior stroke, coronary artery disease, heart fail-
ure (HF), DM, aortic valve disease (aortic regurgitation or stenosis), 
mitral valve disease (mitral regurgitation or stenosis), hypertrophic 
cardiomyopathy, chronic obstructive pulmonary disease (COPD), 
anemia, and malignancy than subjects with P-RF (all P < .05), Table 1. 
There was no significant difference in terms of prior bleeding history 
across the groups, Table 1.
3.3 | Stroke and bleeding risk factors
Mean CHA2DS2-VASc and HAS-BLED score values were higher in pa-
tients with SD-RF and MD-RF than in patients with P-RF (all P < .05), 
Table 1. The proportion of patients with CHA2DS2-VASc score of ≥2 
and HAS-BLED score of ≥3 was higher in patients with SD-RF and 
MD-RF than in patients with P-RF (both P < .001), Table 1.
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TA B L E  1   Baseline characteristics of patients according to renal function
CG ≥ 50 mL/min
n = 1677
(81.3%)
CG 30-49 mL/min
n = 308
(14.9%)
CG < 30 mL/min
n = 77 (3.8%)
P value (among 
the three 
groups)
Age, mean (SD), years 66.8 ± 10.5 78.4 ± 7.2 77.8 ± 8.2 <.001
Age ≥75 years, n (%) 433 (25.8) 230 (74.7) 50 (64.9) <.001
BMI, mean (SD), kg/m2 28.2 ± 4.4 25.8 ± 4.0 25.7 ± 4.4 <.001
Male sex, n (%) 1012 (60.3) 105 (34.1) 34 (44.2) .796
Current smoker, n (%) 253 (15.1) 25 (8.1) 4 (5.2) <.001
Alcohol abusea , n (%) 84 (5.0) 10 (3.2) 1 (1.3) .147
First-diagnosed AF, n (%) 406 (24.2) 72 (23.4) 22 (28.6) .634
Paroxysmal AF, n (%) 654 (39.0) 80 (26.0) 31 (40.3) <.001
Persistent AF, n (%) 252 (15.0) 44 (14.3) 4 (5.2) .064
Permanent AF, n (%) 616 (36.7) 144 (46.8) 38 (49.4) .001
EHRA symptom score, mean (SD) 2.1 ± 0.8 2.3 ± 0.8 2.4 ± 0.8 <.001
EHRA I, n (%) 376 (22.4) 53 (17.2) 10 (13.0) .025
EHRA II, n (%) 800 (47.7) 131 (42.5) 30 (39.0) .104
EHRA III, n (%) 402 (24.0) 100 (32.5) 30 (39.0) <.001
EHRA IV, n (%) 99 (5.9) 23 (7.5) 7 (9.1) .332
Heart rate, mean (SD), beats per minute 90.7 ± 28.2 93.3 ± 29.4 86.6 ± 29.6 .138
SBP, mean (SD), mm Hg 134.5 ± 20.7 136.0 ± 24.9 127.2 ± 27.9 .006
DBP, mean (SD), mm Hg 81.5 ± 11.9 80.5 ± 13.3 75.7 ± 14.2 <.001
Medical history, n (%)
Hypertension 1298 (77.4) 250 (81.2) 58 (75.3) .294
Hypertension well controlledb  870 (51.9) 161 (52.3) 42 (54.5) .465
Previous stroke 162 (9.7) 39 (12.7) 14 (18.2) .022
Previous TIA 50 (3.0) 13 (4.2) 2 (2.6) .504
CAD 484 (28.9) 107 (34.7) 31 (40.3) .017
MI 202 (12.0) 53 (17.2) 17 (22.1) .134
Prior PCI/stenting 154 (9.2) 27 (8.8) 4 (5.2) .044
Heart failure 594 (35.4) 179 (58.1) 59 (76.6) <.001
LVEF ≤ 40% 281 (16.8) 81 (26.3) 28 (36.4) <.001
Diabetes mellitus 396 (23.6) 97 (31.5) 25 (32.5) .004
Prior bleeding 86 (5.1) 18 (5.8) 4 (5.2) .869
Aortic valve diseasec  150 (8.9) 43 (14.0) 12 (15.6) .006
Mitral valve diseased  416 (24.8) 114 (37.0) 29 (37.7) <.001
DCM 130 (7.8) 22 (7.1) 6 (7.8) .933
HCM 30 (1.8) 7 (2.3) 8 (10.4) <.001
RCM 3 (0.2) 1 (0.3) 0 (0.0) .802
Hyperthyroidism 86 (5.1) 45 (14.6) 7 (9.1) .060
COPD 216 (12.9) 50 (16.2) 21 (27.3) .001
PAD 79 (4.7) 13 (4.2) 2 (2.6) .653
Hypercholesterolemia 704 (42.0) 109 (35.4) 27 (35.1) .054
Anemia 171 (10.2) 88 (28.6) 28 (36.4) <.001
Malignancy 64 (3.8) 29 (9.4) 4 (5.2) <.001
Obesity 415 (24.7) 71 (23.1) 9 (11.7) .018
Hemoglobin (SD), g/L 137.3 ± 18.4 126.3 ± 19.4 122.0 ± 20.1 <.001
(Continues)
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3.4 | AF management settings
In AF patients with SD-RF and MD-RF, the arrythmia was less often the 
main reason for hospitalization at enrolling visit than in those with P-RF 
(P < .001); the former were more likely to be hospitalized for HF than those 
with P-RF (P < .001), Table 2. Most patients were managed by a cardiolo-
gist in an academic healthcare facility and in hospital-based center, Table 2.
3.5 | Diagnostic assessment
Patients with SD-RF and MD-RF were less likely to have thyroid hor-
mones assessment, transthoracic echocardiography, exercise stress 
testing, and Holter monitoring at enrolling visit than those with P-RF 
(all P < .05), Table 2.
3.6 | The multivariate predictors of decreasing 
CrCl according to subgroups based on CG formula 
at baseline
Decreasing CrCl according to subgroups based on CG formula was sig-
nificantly associated with HF, anemia, mean CHA2DS2-VASc score, mean 
HAS-BLED score and the use of loop diuretics on multivariable analysis, (all 
P < .001) Table S1. It was also significantly negatively associated with the 
use of rhythm control strategy, beta-blockers, and angiotensin-converting 
enzyme inhibitors (ACE-I) on multivariable analysis (all P < .001), Table S1.
3.7 | Stroke prevention strategies
Patients with SD-RF and MD-RF were less likely to receive oral antico-
agulant therapy (OAC) alone or in combination with antiplatelet drug(s), 
and more likely to use no antithrombotic therapy or single-antiplatelet 
therapy (SAPT) alone than patients with P-RF (all P < .05), Table 2.
Patients with SD-RF and MD-RF with HAS-BLED score value 
of ≥3 were more likely to receive single-antiplatelet therapy (SAPT) 
alone or no anticoagulation compared to their P-RF counterparts. Of 
SD-RF patients with a CHA2DS2-VASc of ≥2, only 58.4% received 
OAC, and 41.6% were treated with SAPT alone or received no anti-
thrombotic therapy, Figure 1.
3.8 | Arrhythmia-directed management strategies
Patients with SD-RF and MD-RF were less likely to receive rhythm 
control strategy, AF catheter ablation, electrical cardioversion (ECV), 
propafenone, and beta-blockers, and more likely to receive rate con-
trol strategy than those with P-RF (all P < .05), Table 2.
3.9 | Other therapies
Patients with SD-RF and MD-RF are less likely to be medicated with 
ACE-I and statins, and more likely to be treated with loop diuretics 
than patients with P-RF, (all P < .05), Table 2. Interestingly, there was 
no significant difference in AT1 receptor inhibitors use across the 
groups, Table 2.
3.10 | Patients re-allocated to a different 
RF category
Using the MDRD formula, seven patients (0.3%) were reclassified 
to another RF category and, with CKD-EPI formula, a change in RF 
category occurred in 17 patients (0.8%), Table 3.
CG ≥ 50 mL/min
n = 1677
(81.3%)
CG 30-49 mL/min
n = 308
(14.9%)
CG < 30 mL/min
n = 77 (3.8%)
P value (among 
the three 
groups)
CHA2DS2-VASc, mean (SD) 3.0 ± 1.8 4.7 ± 1.4 4.6 ± 1.7 <.001
CHA2DS2-VASc ≥ 2 1371 (81.8) 302 (98.1) 76 (98.7) <.001
HAS-BLED, mean (SD) 1.8 ± 1.2 2.7 ± 1.2 3.1 ± 1.0 <.001
HAS-BLED ≥ 3 408 (24.3) 171 (55.5) 56 (72.7) <.001
Abbreviations: AF, atrial fibrillation; beats per minute. CAD, coronary artery disease; BMI, body mass index; bpm; CHA2DS2-VASc: congestive heart 
failure, hypertension, age ≥ 75 years, diabetes, stroke/transient ischemic attack (TIA), vascular disease, age 65 to 74 years, sex category, COPD, 
chronic obstructive pulmonary disease; DBP, diastolic blood pressure; DCM, dilated cardiomyopathy; eGFR, estimated glomerular filtration rate; 
EHRA, European Heart Rhythm Association; HAS-BLED: hypertension, abnormal renal/liver function, stroke, bleeding history or predisposition, labile 
International Normalised Ratio, elderly (age > 65 years), drugs or alcohol concomitantly, HCM, hypertrophic cardiomyopathy; LVEF, left ventricular 
ejection fraction; MI, myocardial infarction; PAD, peripheral artery disease; PCI, percutaneous coronary intervention; RCM, restrictive cardiomyopathy; 
SBP, systolic blood pressure; SD, standard deviation; TIA, transient ischemic attack.
a>4 units of alcohol per day. 
bWell-controlled hypertension—an average systolic blood pressure <140 mm Hg or an average diastolic blood pressure <90 mm Hg, among patients 
with hypertension. 
cAortic regurgitation or stenosis. 
dMitral regurgitation or stenosis. 
TA B L E  1   (Continued)
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TA B L E  2   Atrial fibrillation management according to renal function
CG ≥ 50 mL/min
n = 1677
(81.3%)
CG 30-49 mL/
min
n = 308
(14.9%)
CG < 30 mL/min
n = 77 (3.8%)
P-value (among 
the three eGFR 
groups)
AF management settings, n (%) (at enrolling visit)
AF was the main reason for the 
hospitalization
921 (54.9) 121 (39.3) 20 (26.0) <.001
ACS was the main reason for the 
hospitalization
124 (7.4) 27 (8.8) 6 (7.8) .705
Hypertension was the main reason for the 
hospitalization
36 (2.1) 10 (3.2) 0 (0.0) .195
HF was the main reason for the 
hospitalization
331 (19.7) 96 (31.2) 36 (46.8) <.001
Healthcare facility in capital city 886 (52.8) 156 (50.6) 25 (32.5) .002
Hospital-based center 1531 (91.3) 276 (89.6) 71 (92.2) .597
Outpatient visit 146 (8.7) 32 (10.4) 6 (7.8) .597
Academic healthcare facility 1324 (79.0) 239 (77.6) 59 (76.6) .715
AF managed by a cardiologist 1371 (81.8) 241 (78.2) 58 (75.3) .154
Diagnostic assessment, n (%) (at enrolling visit)
Routine biochemistry 1675 (99.9) 308 (100.0) 76 (98.7) .574
Thyroid hormones measurement 725 (43.2) 98 (31.8) 18 (23.4) <.001
Transthoracic echocardiography 1518 (90.5) 274 (89.0) 62 (80.5) .010
Holter monitoring (rhythm) 539 (32.1) 62 (20.1) 9 (11.7) <.001
Exercise stress testing 148 (8.8) 7 (2.3) 2 (2.6) <.001
Stroke prevention (at enrolling visit), n (%)
No antithrombotic therapy 159 (9.1) 31 (10.1) 15 (19.5) .016
Overall OAC 1266 (75.5) 205 (66.6) 45 (58.4) <.001
OAC alone 1060 (63.2) 175 (56.8) 37 (48.1) .005
VKA 1010 (60.2) 164 (53.2) 41 (53.2) .041
TTR ≥65% 166 (16.4) 23 (14.0) 0 (0.0) .823
Acenocoumarol 653 (38.9) 105 (34.1) 20 (26.0) .025
Warfarin 357 (21.3) 59 (19.2) 21 (27.3) .290
Phenprocoumon 0 (0.0) 0 (0.0) 0 (0.0)
NOAC 256 (15.3) 41 (13.3) 4 (5.2) .039
Dabigatran 150 mg BID 86 (5.1) 0 (0.0) 0 (0.0) <.001
Dabigatran 110 mg BID 51 (3.0) 18 (5.8) 1 (1.3) <.001
Rivaroxaban 80 (4.8) 14 (4.5) 3 (3.9) .929
Apixaban 36 (2.1) 9 (2.9) 0 (0.0) .285
Single-antiplatelet therapy alone 175 (10.4) 54 (17.5) 14 (18.2) <.001
Aspirin (alone or with OAC) 421 (25.1) 93 (30.2) 23 (29.9) .130
Clopidogrel or ticlopidine (alone or with OAC) 164 (9.8) 34 (11.0) 7 (9.1) .771
Prasugrel or ticagrelor (alone or with OAC) 5 (0.2) 0 (0.0) 0 (0.0) .563
DAPT alone 76 (4.5) 18 (5.8) 3 (3.9) .574
Dual antithrombotic therapy 149 (8.9) 23 (7.5) 6 (7.8) .691
Triple antithrombotic therapy 57 (3.4) 7 (2.3) 2 (2.6) .559
Symptom management, n (%)
Rhythm control 645 (38.5) 75 (24.4) 16 (20.8) <.001
Rate control 935 (55.8) 207 (67.2) 47 (61.0) <.001
(Continues)
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3.11 | Characteristics of AF patients with HF 
according to their RF
Patients with SD-RF and MD-RF with HF had higher mean HAS-
BLED score than patients with P-RF (P < .001). They were more 
likely to have anemia and to receive no antithrombotic therapy and 
SAPT alone than patients with P-RF (all P < .05). Individuals with 
SD-RF and MD-RF with HF were less likely to be male, to had prior 
PCI/ stenting, hypercholesterolemia and to be medicated with OAC 
overall, OAC alone, beta-blockers, ACE-I and AT1 receptor blockers 
than patients with P-RF (all P < .05), Table S2.
4  | DISCUSSION
This study provides novel insights into clinical practice from the larg-
est published prospective AF registry from the Balkans, a European 
region that has been under-represented in many prior studies. In our 
study, 3.8% of enrolled patients had SD-RF, in line with other regis-
tries where the prevalence of patients with SD-RF ranged from 2.0% 
to 3.7%.11,21,22
CG ≥ 50 mL/min
n = 1677
(81.3%)
CG 30-49 mL/
min
n = 308
(14.9%)
CG < 30 mL/min
n = 77 (3.8%)
P-value (among 
the three eGFR 
groups)
Non-pharmacological AF therapies (at enrolment or in future), n (%)
AF catheter ablation 57 (3.4) 1 (0.3) 1 (1.3) .008
ECV 65 (3.9) 4 (1.3) 0 (0.0) .017
AV node ablation with PM implantation 7 (0.4) 2 (0.6) 0 (0.0) .724
Pharmacological AF therapies (at enrolment), 
n (%)
Digoxin 366 (21.8) 98 (31.8) 13 (16.9) <.001
Verapamil, diltiazem 89 (5.30) 21 (6.8) 5 (6.5) .647
Beta blockers 1212 (72.3) 200 (64.9) 46 (59.7) .003
Propafenone 205 (12.2) 7 (2.3) 0 (0.0) <.001
Flecainide 1 (0.1) 1 (0.3) 1 (1.3) .014
Sotalol 15 (0.9) 1 (0.3) 0 (0.0) .697
Amiodarone 435 (25.9) 73 (23.7) 22 (28.6) .597
Dronedarone 1 (0.1) 1 (0.3) 0 (0.0) .375
Dofetilide 0 (0.0) 0 (0.0) 0 (0.0)
Other therapy, n (%) (at enrolment)
ACE-I 830 (49.5) 135 (43.8) 25 (32.5) .004
AT1 receptor blockers 326 (19.4) 59 (19.2) 12 (15.6) .701
Loop diuretics 622 (37.1) 159 (51.6) 51 (66.2) .012
Statins 715 (42.6) 117 (38.0) 21 (27.3) <.001
Abbreviations: ACE-I, angiotensin-converting enzyme inhibitor; ACS, acute coronary syndrome; AF, atrial fibrillation; AV, atrioventricular, CG, 
Cockcroft-Gault; DAPT, dual antiplatelet therapy; ECV, electrical cardioversion; eGFR, estimated glomerular filtration rate; HF, heart failure; NOAC, 
nonvitamin K oral anticoagulants; OAC, oral anticoagulants; PM, pacemaker; TTR, time in therapeutic range; VKA, vitamin K antagonist.
TA B L E  2   (Continued)
F I G U R E  1   Stroke prevention strategies in patients with AF 
according to CrCl based on CG formula. AF, atrial fibrillation, 
CHA2DS2-VASc: congestive heart failure, hypertension, age 
≥75 years, diabetes, stroke/transient ischemic attack (TIA), vascular 
disease, age 65-74 years, sex category, CG, Cockcroft-Gault, CrCl, 
creatinine clearance, eGFR; estimated glomerular filtration rate, 
HAS-BLED: hypertension, abnormal renal/liver function, stroke, 
bleeding history or predisposition, labile International Normalised 
Ratio, elderly (age >65 years), drugs or alcohol concomitantly, 
OAC; oral anticoagulants
870  |     KOZIEŁ Et al.
The main findings of our study were as follows: (a) different de-
mographic, cardiovascular risk, and AF-related profile of patients 
according to RF, (b) differences in the management of AF across the 
RF categories, including lower use of OAC for stroke prevention in 
patients with SD-RF and MD-RF than in those with P-RF, whereas 
the use of rate control strategy, SAPT alone and no antithrombotic 
therapy was higher in subjects with SD-RF and MD-RF than in those 
with P-RF, and (c) no profound differences in terms of NOAC dosing 
or avoidance of prescription with the use of MDRD or CKD-EPI in-
stead of CG formula.
4.1 | Demographic, cardiovascular risk, and AF-
related profile
In this study sex distribution among the different subgroups is un-
expected. Patients with preserved/mildly depressed renal function 
(RF) were more likely to be men, while patients with moderately and 
severely depressed RF were more likely to be women. However, the 
number of patients with preserved/mildly depressed RF is greater 
than those with moderately or severely depressed RF, thus the latter 
can be underpowered. Moreover, patients in the BALKAN-AF data-
set are more likely to be men, thus women may be underpowered in 
the group with preserved/ mildly depressed RF which is the largest 
group.
Patients with SD-RF and MD-RF were older, similar to other 
reports23, and more symptomatic than those with P-RF. The higher 
mean EHRA symptom score in patients with SD-RF and MD-RF may 
reflect higher burden of comorbid conditions. In contrast to our 
study, AF patients with severely compromised RF were more fre-
quently asymptomatic in another study.22 In our cohort, 23% of pa-
tients with MD-RF and 28% of those with SD-RF had first-diagnosed 
AF. Reportedly, up to 45% of patients with moderate to severe CKD 
may have newly diagnosed AF.23
A pattern similar to our study was also seen in a Chinese 
cross-sectional survey 3 where patients with low eGFR were 
older, more likely to have cardiovascular disease (among others, 
hypertension, and DM) than subjects without indicators of kidney 
damage.
In our study, patients with SD-RF and MD-RF were more likely 
to have HF than those with P-RF. This was also seen in other stud-
ies.22,23 Baseline renal impairment and worsening of RF occurred 
frequently in patients with acute and chronic HF. Moreover, any 
degree of renal function impairment should be considered as signifi-
cant risk stratifier in patients with HF.24
4.2 | Stroke and bleeding risk and stroke prevention
In our study, patients with SD-RF and MD-RF were older, with more 
concomitant diseases including HF, hypertension, DM, prior stroke than 
those with P-RF and therefore were more likely to have higher stroke 
and bleeding risk. Those findings are consistent with prior datasets.23
In our study, the proportion of patients with SD-RF and MD-RF 
medicated with OAC (66% and 58%, respectively) was lower than in a 
recent European registry.22 However, in the Danish nationwide cohort 
and the Swedish AF Cohort study, the use of VKA among CKD patients 
was lower than in our study11,25, with a high prevalence of no antithrom-
botic therapy or use of antiplatelets only in patients with SD-RF and MD-
RF. Despite increased stroke risk in patients with SD-RF, 41.6% of these 
patients was not anticoagulated in the Balkan region.26 Importantly, 
guideline-adherent anticoagulant therapy is associated with significantly 
better outcomes among AF patients.27 The inappropriately low use of 
OAC in patients with SD-RF and MD-RF is a significant knowledge gap in 
AF management in daily clinical practice in the Balkans. In our study, the 
quality of anticoagulation was poor with less than a quarter of patients 
having a Time in Therapeutic Range ≥65%. In one nationwide observa-
tional cohort study28, patients with CKD and CHA2DS2-VASc score ≥ 2 
had significantly lower risk of all-cause mortality with vs without warfa-
rin treatment for stroke prevention. In the Balkan region, management 
with NOAC was less prevalent in patients with SD-RF and MD-RF, partly 
owing to a lack of appropriate NOAC reimbursement policy in some 
Balkan countries. However, 5% of patients with SD-RF was medicated 
with NOAC despite contraindications.6,26 Patients with AF and CKD had 
increased risk of bleeding.1,29 However, only one patient received an al-
ternative to OAC (ie, left atrial appendage occlusion).
4.3 | Arrhythmia-directed management strategies
In the BALKAN-AF survey, patients with SD-RF and MD-RF were more 
likely to receive rate control strategy, whereas patients with P-RF were 
more likely to undergo a rhythm control strategy. This approach may 
be related to the perception of greater odds of irreversible substrate 
TA B L E  3   Number and proportion of patients allocated to the 
different classes of renal function, changed according to equations, 
for renal function assessment, different than CG
Class of renal function according 
to CG MDRD, n (%)
CKD-EPI, 
n (%)
CrCl < 30 mL/min (SD-RF), n = 77 
(3.8%)
84 (100.0) 88 (100.0)
0 (0.0) 0 (0.0)
0 (0.00 0 (0.0)
CrCl 30-49 mL/min (MD-RF), 
n = 308 (14.9%)
7(2.3) 11(3.6)
301 (97.7) 291 (94.5)
0 (0.0) 6 (1.9)
CrCl ≥ 50 ml/min (P-RF), n = 1677 
(81.3%)
0 (0.0) 0 (0.00
0 (0.00) 0 (0.0)
1677 (100.0) 1683 (100.0)
Note: Bold represents MD-RF, italics represents SD-RF.
Abbreviations: CG, Cockcroft-Gault, CKD-EPI, Chronic Kidney Disease 
Epidemiology Collaboration group, CrCl, creatinine clearance, MDRD, 
modification of diet in renal disease, MD-RF, moderately depressed 
renal function, P-RF, preserved/mildly depressed renal function, SD-RF, 
severely depressed RF.
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for AF in patients with SD-RF and MD-RF. Similarly, in the European 
Heart Rhythm Association Survey, rhythm control strategy was not pre-
ferred in patients with more advanced CKD, probably due to the lower 
expected success rate and limited data on safety of antiarrhythmic drugs 
in those patients.30 The prevalence of ECV across three subgroups was 
very low. Despite higher prevalence of permanent AF in patients with 
SD-RF and MD-RF, there were no significant differences in amiodarone 
use across three RF categories. Moreover, amiodarone may be overused 
in the Balkan region, possibly representing another knowledge gap in 
the real-world management of AF patients in the region.
In our study, patients with SD-RF and MD-RF were less likely to 
have AF catheter ablation than those with P-RF. However, AF catheter 
ablation tends to be increasingly used for rhythm control globally, in-
cluding challenging patients with complex comorbidities.1 Maintenance 
of sinus rhythm after AF catheter ablation in patients with SD-RF has 
been shown to be associated with a significant improvement in RF.31 
However, the risk of vascular complications associated with ablation is 
elevated in CKD patients in comparison with patients with normal RF.32
4.4 | Different equations for estimating RF
In our cohort, no profound differences would appear in terms of 
NOAC dosing or avoidance of prescription using MDRD and CKD-
EPI formula instead of the CG equation. Only <1% of patients using 
MDRD formula and <1% of those using CKD-EPI formula would 
be affected by changes in NOAC dosing or avoidance of NOACs. 
Importantly, the precision of CG formula in estimating RF is ques-
tionable, especially among the elderly or those with increased body 
mass index (BMI).33 In a comparative study34, CG formula provided 
less accurate estimation of GFR than CKD-EPI and MDRD.
However, another study35 showed that changes in NOAC ther-
apy could appear using GFR formulas rather than CrCl in 16.9% of 
patients using MDRD formula and in 14.7% of subjects using CKD-
EPI. The most important changes in RF assessment were revealed in 
patients aged ≥75 years, but also BMI had a significant impact.
4.5 | Limitations
This study is limited by its observational design, and follow-up data 
were not collected. There are no data regarding patient/prescriber 
treatment preferences. Possible selection bias may appear owing to 
variable healthcare setting in participating countries. Differences 
in healthcare systems in different countries could have influenced 
the availability of specific drugs (eg, NOACs). A status of compli-
ance with guidelines may vary according to countries. However, we 
have analyzed the totality of data for this study (which focuses on 
CKD) and country-specific analyses are planned. Information re-
garding dose adjustment with digoxin and sotalol is not collected. 
Albuminuria, which is a component for the evaluation of kidney 
function was not assessed. Moreover, physicians knew that their 
recommendations on diagnostic assessment and treatment would be 
recorded. Registries are likely to attract selected highly motivated 
patients and their treatment at enrolling visit may express higher 
compliance. However, because of enrolment of consecutive pa-
tients, the probability for a physician to recruit mainly patients with 
higher compliance is limited. Future prospective studies are needed 
to complement our results.
4.6 | Strengths
Strengths of the study are the Balkan study setting and the prospec-
tive study design complementing published trials and registries.
5  | CONCLUSIONS
In the BALKAN-AF survey, patients with SD-RF and MD-RF were 
older, more symptomatic, had higher stroke and bleeding risk and 
more comorbidities than those with P-RF. They were less likely to 
receive OAC, AF catheter ablation or ECV, and more likely to use 
rate control strategy, SAPT alone and no antithrombotic therapy 
than subjects with P-RF. There would be no profound differences 
in terms of NOAC dosing or avoidance of prescription using MDRD 
and CKD-EPI formula. Our study highlighted important local 
knowledge gaps in clinical practice that may inform targeted edu-
cation interventions.
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